^
    Back
    Association details:
    Biomarker:CD133 expression
    Cancer:Colon Cancer
    Drug:CD133-specific CAR-T cell therapy (CD133-targeted CAR-T immunotherapy) +
    entolimod (STAT-600) (Apoptosis inhibitor, TLR5 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Biol Med
    Title:

    The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer

    Published date:
    07/17/2023
    Excerpt:
    Furthermore, in hCD133+/hCD133− mixed cancer xenograft models, CAR133-i502-NK92 cells suppressed cancer growth better than the counterparts (n = 5, P = 0.0297). Greater T-cell infiltration was associated with greater anti-tumor potency (P < 0.0001)….Armed with a CBLB502 TLR5 agonist, CAR133-NK92 cells were shown to be capable of specifically eliminating CD133-positive colon cancer cells in a CAR133-dependent manner and indirectly eradicating CD133-negative colon cancer cells in a CBLB502-specific endogenous immune response manner.
    DOI:
    https://doi.org/10.20892/j.issn.2095-3941.2023.0033